Physiomics wins small contract with European biotech client

Cancer treatment prediction technology developer Physiomics has been awarded a contract by a new European biotech client, it announced on Thursday.

The AIM-traded firm said the value of the contract was £55k, and it was expected to complete in the current calendar year.

It said the initial project would focus on the pre-clinical characterisation of an “exciting” new anti-cancer agent.

The client had reportedly expressed the desire for a partner to support them in the period leading up to and during their agent's early clinical studies.

“We are very excited to have signed our fourth new client of 2018 and look forward to working with them over the balance of this year,” said Physiomics chief executive officer Dr Jim Millen.